Abstract
Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Current Neuropharmacology
Title: Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Volume: 2 Issue: 3
Author(s): Christian Czech and Celine Adessi
Affiliation:
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Abstract: Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Export Options
About this article
Cite this article as:
Czech Christian and Adessi Celine, Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359666
DOI https://dx.doi.org/10.2174/1570159043359666 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Lenticulostriate Artery and Lenticulostriate-artery Neural Complex: New Concept for Intracerebral Hemorrhage
Current Pharmaceutical Design The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment
Current Alzheimer Research The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Adolescent HIV-1 Transgenic Rats: Evidence for Dopaminergic Alterations in Behavior and Neurochemistry Revealed by Methamphetamine Challenge
Current HIV Research Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets Commentary: Histaminergic Drugs Could be Novel Targets for Neuroprotection in CNS Disorders
CNS & Neurological Disorders - Drug Targets Evaluation of Insulin Resistance Induced Brain Tissue Dysfunction in Obese Dams and their Neonates: Role of Ipriflavone Amelioration
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Statistical Signal Processing in the Analysis, Characterization and Detection of Alzheimer's Disease)
Current Alzheimer Research Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design Alzheimer's Disease Prevention and Use of Traditional Plant Medicines
Letters in Drug Design & Discovery Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews